Monthly update from the PB3 Personal Health Fund. “LP” (Limited Paul’s) is my network following along; “GP” (Genuine Paul) is the accountable, aspirational version of myself trying to show up. No real fund, investors, or capital exist — this is a personal brand device for tracking health, energy, and research the same way I’d track a portfolio.

July was the founding month. Baseline was set June 29th, and everything below is measured against that starting line.

Metrics — Month at a Glance

Metric	Start of Month (Baseline)	End of Month	Shift
Health Score	829/900	844/900	↑ new high, above baseline
Biological Age	31 (vs. 37 chronological)	31 (vs. 37 chronological)	Holding — 6 years of headroom
Pace of Aging	0.3x	0.1x	↑ significant improvement
HRV	47.8 ms	~53.6 ms	↑ consistently up all month
Sleep (avg)	8h47m	7h24m	↓ net, but volatile — see misses below
Weekly Steps (avg)	High tier	High–Very High tier	Consistent
Blood Pressure	122/71	122–123/70–71	Flat — boring in the best way

Recovery is a daily-only metric on the Hume Band and doesn’t aggregate cleanly at the monthly level, so I’m not reporting a trend line for it yet. Baseline flagged it as the softest metric in the founding week, and it’s worth a dedicated look once I have a cleaner way to track it over time.

The one number that matters most this month: Pace of Aging dropped from 0.3x to 0.1x. It’s the clearest signal that whatever I did this month, on balance, moved the right direction, even with a genuinely rough patch in the middle.

Top Wins

• Health Score hit a new high (844) mid-month, above baseline — even alongside a sleep dip, which says something about how the underlying trend is more robust than any single week’s noise.
• Metabolic Capacity climbed hard early — 56 → 76 → 91 (“Excellent”) across the first three weeks, the single fastest-moving metric of the month.
• NeuroNYC’s first-ever investor happy hour — hosted mid-month, ~21–22 of 53 RSVPs attended. Roughly 50% attrition, which is in line with typical turnout for a first event. It happened, people showed up, and it’s a real foundation to build the Q4 follow-up event on.
• The research and writing muscle got real reps this month — my weekly research format went through multiple honest revisions (too dense → too thin → right-sized), landing on something built around depth over page count, with visuals and diagrams instead of walls of text.

Top Misses / What Didn’t Work

• Gym consistency broke down. Started the month at a real 3x/week cadence, then a full deload week (reframed honestly: environment upgrades, not just a miss), then inconsistent execution the rest of the month — alarms not sticking, sessions skipped. This is something I want to turn around going into August.
• Sleep trended down for three straight weeks before rebounding late in the month — 7h12m → 7h22m → 5h49m, then back up to 7h24m. The dip coincided almost exactly with the gym inconsistency.

Adjustments Going Into August

• Testing a midday gym slot instead of early morning, using babysitter coverage on Tue/Wed/Thu as the window. Early mornings had three straight weeks to prove out and didn’t stick — time to test a different hypothesis rather than repeat the same one and hope.
• Treating sleep as a leading indicator, not a lagging one. The gym misses and the sleep dip moved together this month; going forward, a bad sleep stretch is a cue to protect the next few nights, not just a data point to log.

Thesis Pillar Roundup

Longevity: The big thread this month was epigenetic clock validation. Where the field is both more confident (pace-of-aging methodology, longitudinal tracking) and more openly contested (static single-timepoint clocks, blinding and noise problems) than the marketing around biological age tests usually lets on. Practical takeaway I’m carrying forward: the gap between biological and chronological age matters more than the absolute number, and multi-clock triangulation beats any single reading — including my own.

Mental Health: This became the highest-conviction pillar of the month. tDCS moved from “one option among three” to clear top priority after the FDA approved the first at-home tDCS device for depression (Flow Neuroscience’s FL-100, approved December, rolling out through this year) — it’s the first concrete proof point that the reimbursement thesis I’ve been writing about isn’t hypothetical. tFUS stays close behind on the strength of reaching subcortical targets TMS structurally can’t. Also mapped two major NYC-anchored raises this month worth knowing about regardless of thesis: Talkiatry’s $210M Series D and Flourish’s $500M round.

Brain Health: Started a running foundational neuroscience thread this month — the HPA axis (the stress-cortisol circuit) and sleep architecture/the glymphatic system, the brain’s overnight waste-clearance process that runs hardest during deep sleep specifically. Both ended up directly relevant to my own data in a way I didn’t fully expect when I picked the topics. This adjustment is less about my thesis and more about general neuro knowledge.

BCI: Mapped the competitive landscape properly for the first time — Neuralink, Synchron, Science Corp (a serious contender for “first commercial BCI,” backed by Neuralink’s own co-founder), Precision Neuroscience (NYC-based, another Neuralink co-founder, minimally invasive), and Neuracle’s NEO device in China, which claimed the first actual commercial BCI implant globally in July. Longer-dated thesis pillar than the others, but the field moved fast this month.

NeuroNYC / Network

• First investor happy hour done! (See above in Top Wins for photos!)
• Ken Shepherd raised an idea at the NeuroNYC AI Summit about injectable biometric chips communicating with wearables — this got me curious about a BCI-adjacent thread. Worth a proper look down the line; however, this interests me and motivates me to learn more about how to improve accuracy with my own biometric data.
• Q4 Investor happy hour is next!

Personal / Life Context

The environment investment this month? Air purifiers & better temperature control at home. It was a deliberate bet that recovery infrastructure compounds the same way a workout does, even though it cost a full week of gym consistency to install. I’d make that trade again, but I’m also not going to pretend it was free. Nutrition shifted toward fresher, whole-food ingredients this month, and I reconnected with a group of old friends at a wedding (Shoutout Matt Kennedy!) — good reminder that the network pillar isn’t only professional.

The Take

If I had to bet on one thing from this month mattering most a year from now, it’s the tDCS FDA approval. It’s the first real evidence that the “venture-subsidized mental health category becomes a durable, reimbursed business” is a thesis that can actually resolve in real time. I’ll be watching for a CPT code filing as the next concrete signal :fingerscrossed:

---

“LP” and “GP” are a personal brand device used for self-tracking purposes only. No real fund, investors, or capital exist.